Literature DB >> 21320114

A population-based study of long-term outcomes of cryptogenic focal epilepsy in childhood: cryptogenic epilepsy is probably not symptomatic epilepsy.

Elaine C Wirrell1, Brandon R Grossardt, Elson L So, Katherine C Nickels.   

Abstract

PURPOSE: To compare long-term outcome in a population-based group of children with cryptogenic versus symptomatic focal epilepsy diagnosed from 1980 to 2004 and to define the course of epilepsy in the cryptogenic group.
METHODS: We identified all children residing in Olmsted County, MN, 1 month through 17 years, with newly diagnosed, nonidiopathic focal epilepsy from 1980 to 2004. Children with idiopathic partial epilepsy syndromes were excluded. Medical records were reviewed to determine etiology, results of imaging and EEG studies, treatments used, and long-term outcome. Children were defined as having symptomatic epilepsy if they had a known genetic or structural/metabolic etiology, and as cryptogenic if they did not. KEY
FINDINGS: Of 359 children with newly diagnosed epilepsy, 215 (60%) had nonidiopathic focal epilepsy. Of these, 206 (96%) were followed for > 12 months. Ninety-five children (46%) were classified as symptomatic. Median follow-up from diagnosis was similar in both groups, being 157 months (25%, 75%: 89, 233) in the cryptogenic group versus 134 months (25%, 75%: 78, 220) in the symptomatic group (p = 0.26). Of 111 cryptogenic cases, 66% had normal cognition. Long-term outcome was significantly better in those with cryptogenic versus symptomatic etiology (intractable epilepsy at last follow-up, 7% vs. 40%, p < 0.001; seizure freedom at last follow-up, 81% vs. 55%, p < 0.001). Of those who achieved seizure freedom at final follow-up, 68% of the cryptogenic group versus only 46% of the symptomatic group were off antiepileptic medications (p = 0.01). One-third of the cryptogenic group had a remarkably benign disorder, with no seizures seen after initiation of medication, or in those who were untreated, after the second afebrile seizure. A further 5% had seizures within the first year but remained seizure-free thereafter. With the exception of perinatal complications, which predicted against seizure remission, no other factors were found to significantly predict outcome in the cryptogenic group. SIGNIFICANCE: More than half of childhood nonidiopathic localization-related epilepsy is cryptogenic. This group has a significantly better long-term outcome than those with a symptomatic etiology, and should be distinguished from it. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2011        PMID: 21320114      PMCID: PMC3076935          DOI: 10.1111/j.1528-1167.2010.02969.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  18 in total

1.  A population-based survey of childhood epilepsy in Okayama Prefecture, Japan: reclassification by a newly proposed diagnostic scheme of epilepsies in 2001.

Authors:  Tomoyuki Akiyama; Katsuhiro Kobayashi; Tatsuya Ogino; Harumi Yoshinaga; Eiji Oka; Makio Oka; Minako Ito; Yoko Ohtsuka
Journal:  Epilepsy Res       Date:  2006-07-11       Impact factor: 3.045

2.  The accuracy of outcome prediction models for childhood-onset epilepsy.

Authors:  Miranda Geelhoed; Anne Olde Boerrigter; Peter Camfield; Ada T Geerts; Willem Arts; Bruce Smith; Carol Camfield
Journal:  Epilepsia       Date:  2005-09       Impact factor: 5.864

3.  Prevalence, classification, and severity of epilepsy in children in western Norway.

Authors:  P E Waaler; B H Blom; H Skeidsvoll; A Mykletun
Journal:  Epilepsia       Date:  2000-07       Impact factor: 5.864

4.  Distribution of epilepsy syndromes in a cohort of children prospectively monitored from the time of their first unprovoked seizure.

Authors:  S Shinnar; C O'Dell; A T Berg
Journal:  Epilepsia       Date:  1999-10       Impact factor: 5.864

5.  Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009.

Authors:  Anne T Berg; Samuel F Berkovic; Martin J Brodie; Jeffrey Buchhalter; J Helen Cross; Walter van Emde Boas; Jerome Engel; Jacqueline French; Tracy A Glauser; Gary W Mathern; Solomon L Moshé; Douglas Nordli; Perrine Plouin; Ingrid E Scheffer
Journal:  Epilepsia       Date:  2010-02-26       Impact factor: 5.864

6.  Discontinuation of anticonvulsant therapy in children with partial epilepsy.

Authors:  A Verrotti; S Morresi; F Basciani; R Cutarella; G Morgese; F Chiarelli
Journal:  Neurology       Date:  2000-11-14       Impact factor: 9.910

7.  Two-year remission and subsequent relapse in children with newly diagnosed epilepsy.

Authors:  A T Berg; S Shinnar; S R Levy; F M Testa; S Smith-Rapaport; B Beckerman; N Ebrahimi
Journal:  Epilepsia       Date:  2001-12       Impact factor: 5.864

8.  Development of syndrome severity scores for pediatric epilepsy.

Authors:  David W Dunn; Janice M Buelow; Joan K Austin; Shlomo Shinnar; Susan M Perkins
Journal:  Epilepsia       Date:  2004-06       Impact factor: 5.864

Review 9.  Imaging of malformations of cortical development.

Authors:  Nadia Colombo; Noriko Salamon; Charles Raybaud; Cigdem Ozkara; A James Barkovich
Journal:  Epileptic Disord       Date:  2009-09-01       Impact factor: 1.819

Review 10.  Epileptic syndromes in childhood: clinical features, outcomes, and treatment.

Authors:  Peter Camfield; Carol Camfield
Journal:  Epilepsia       Date:  2002       Impact factor: 5.864

View more
  10 in total

1.  Neurological autoantibodies in drug-resistant epilepsy of unknown cause.

Authors:  Mehmet Tecellioglu; Ozden Kamisli; Suat Kamisli; Fatma Ebru Yucel; Cemal Ozcan
Journal:  Ir J Med Sci       Date:  2018-03-09       Impact factor: 1.568

2.  Complete remission of childhood-onset epilepsy: stability and prediction over two decades.

Authors:  Anne T Berg; Karen Rychlik; Susan R Levy; Francine M Testa
Journal:  Brain       Date:  2014-10-22       Impact factor: 13.501

3.  A tale of two cohorts: Differing outcomes in infantile-onset focal epilepsy.

Authors:  Erin M Triplet; Katherine Nickels; Lily Wong-Kisiel; Anthony Fine; Elaine C Wirrell
Journal:  Epilepsia       Date:  2022-02-10       Impact factor: 5.864

4.  What predicts enduring intractability in children who appear medically intractable in the first 2 years after diagnosis?

Authors:  Elaine C Wirrell; Lily C-L Wong-Kisiel; Jay Mandrekar; Katherine C Nickels
Journal:  Epilepsia       Date:  2013-04-03       Impact factor: 5.864

5.  Long-term follow-up of a large cohort with focal epilepsy of unknown cause: deciphering their clinical and prognostic characteristics.

Authors:  Arife Çimen Atalar; Ebru Nur Vanlı-Yavuz; Ebru Yılmaz; Nerses Bebek; Betül Baykan
Journal:  J Neurol       Date:  2019-12-02       Impact factor: 4.849

6.  The Peptide Network between Tetanus Toxin and Human Proteins Associated with Epilepsy.

Authors:  Guglielmo Lucchese; Jean Pierre Spinosa; Darja Kanduc
Journal:  Epilepsy Res Treat       Date:  2014-06-01

7.  Is the anatomical lesion always guilty?: A case report.

Authors:  Veronica Pelliccia; Francesco Cardinale; Ginevra Giovannelli; Laura Castana; Marco de Curtis; Laura Tassi
Journal:  Epilepsy Behav Rep       Date:  2022-08-29

8.  Temporal lobe epilepsy in children.

Authors:  Katherine C Nickels; Lily C Wong-Kisiel; Brian D Moseley; Elaine C Wirrell
Journal:  Epilepsy Res Treat       Date:  2011-10-20

Review 9.  Patient considerations in the management of focal seizures in children and adolescents.

Authors:  Daniel Kenney; Elaine Wirrell
Journal:  Adolesc Health Med Ther       Date:  2014-04-09

Review 10.  Genetic Landscape of Common Epilepsies: Advancing towards Precision in Treatment.

Authors:  Sarita Thakran; Debleena Guin; Pooja Singh; Priyanka Singh; Samiksha Kukal; Chitra Rawat; Saroj Yadav; Suman S Kushwaha; Achal K Srivastava; Yasha Hasija; Luciano Saso; Srinivasan Ramachandran; Ritushree Kukreti
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.